Trinity Biotech Files 6-K, Confirms 20-F Reporting
Ticker: TRIB · Form: 6-K · Filed: Aug 29, 2024 · CIK: 888721
| Field | Detail |
|---|---|
| Company | Trinity Biotech PLC (TRIB) |
| Form Type | 6-K |
| Filed Date | Aug 29, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $1,870,000, $0.0109 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, procedural, foreign-private-issuer
TL;DR
Trinity Biotech filed a 6-K confirming they'll use 20-F for annual reports. No new info.
AI Summary
Trinity Biotech plc filed a Form 6-K on August 29, 2024, to report its status as a foreign private issuer. The filing confirms that the company will file its annual reports under cover of Form 20-F. No specific financial or operational details beyond this procedural information were provided in this particular filing.
Why It Matters
This filing is a routine procedural update for foreign private issuers, confirming their reporting framework with the SEC and does not contain new operational or financial information.
Risk Assessment
Risk Level: low — This is a routine procedural filing by a foreign private issuer and does not contain new material information that would impact risk.
Key Players & Entities
- TRINITY BIOTECH PLC (company) — Registrant
- IDA Business Park Bray, County. Wicklow, Ireland (location) — Principal Executive Office
- Form 6-K (document) — Filing type
- Form 20-F (document) — Annual report cover
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K filing is to report that Trinity Biotech plc is a foreign private issuer and will file its annual reports under cover of Form 20-F.
When was this Form 6-K filed?
This Form 6-K was filed on August 29, 2024.
What is the principal executive office address for Trinity Biotech plc?
The principal executive office address is IDA Business Park, Bray, County. Wicklow, Ireland.
Does Trinity Biotech plc file its annual reports under Form 20-F or Form 40-F?
Trinity Biotech plc files its annual reports under cover of Form 20-F.
Does this filing contain specific financial results or operational updates?
No, this filing is a procedural report confirming the company's reporting status and does not contain specific financial results or operational updates.
Filing Stats: 394 words · 2 min read · ~1 pages · Grade level 12.8 · Accepted 2024-08-29 06:01:30
Key Financial Figures
- $1,870,000 — he Company may sell up to an additional $1,870,000 American Depositary Shares ("ADSs"), ea
- $0.0109 — Company's A Ordinary Shares, par value $0.0109 per share, from time to time, through C
Filing Documents
- zk2431954.htm (6-K) — 15KB
- exhibit_5-1.htm (EX-5.1) — 79KB
- image0.jpg (GRAPHIC) — 32KB
- image00003.jpg (GRAPHIC) — 635KB
- image00005.jpg (GRAPHIC) — 499KB
- image00006.jpg (GRAPHIC) — 38KB
- 0001178913-24-002843.txt ( ) — 1754KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TRINITY BIOTECH PLC Trinity Biotech plc (Registrant) By: /s/John Gillard John Gillard Chief Executive Officer Date: August 29, 2024